马来西亚药品和医疗行业2011年第二季度研究报告——Malaysia Pharmaceuticals and Healthcare Report Q2 2011

纸介版价格:美元/篇 页数:112页上传日期:2011-05-18
电子版价格:530美元/篇
纸介版+电子版价格:美元 附件下载:点击下载PDF        点击下载Word       
关键字: 马来西亚|药品和医疗行业|Malaysia |Pharmaceuticals and Healthcare |

发布日期:2011年3月


摘要

"Malaysia's pharmaceutical market potential is likely to be fulfilled in the longer term. For the time being, we view the market as a moderately attractive regional prospect. In BMI’s Business Environment Ratings (BER) matrix for Q211, Malaysia remains placed eighth, out of the 17 markets surveyed. The key attractions of the Malaysian pharmaceutical market over the longer term will continue to be the government’s encouragement of the biotechnology sector, the improving regulatory environment and the country’s economic development, which will allow for higher public as well as private expenditure on pharmaceuticals. On the other hand, per-capita pharmaceutical consumption is quite low, especially due to the high out-of-pocket payment levels, which make the market vulnerable to economic downturns.
The market is based on a strong domestic generics sector and imports of branded and patented medicines (mostly from the US, Japan and Germany). Pharmaceutical spending represented an estimated 0.62% of GDP in 2010. Through to 2015, the Malaysian drug market, valued at around MYR4.57bn (US$1.40bn) in 2010, is expected to post a compound annual growth rate (CAGR) of 6.93% in local currency terms, supported by demographic and economic changes as well as by calls to improve access to medical services through the implementation of the National Healthcare Financing Scheme. This momentum is expected to be maintained over the following five years, with the 2010-2020 CAGR also coming in at 6.93%. Generics will be the best performing segment, posting a 9.25% CAGR to 2020.
The above outlook is supported by development such as the announcement that the Malaysian government is looking to raise quality and technical standards in the local pharmaceutical industry by tightening bioequivalence rules. The government will implement new regulations by 2012, under which all generic drugs submitted for approval in the country will have to present bioequivalence to a selected branded comparator product. According to Health Minister Dato’ Sri Liow Tiong Lai, the regulations will bring the local pharmaceutical industry in line with international standards, allowing exports to an increasing number of markets.
However, while we expect the Malaysian economy to continue expanding steadily, we are concerned at the looming risk of a severe double-dip slowdown in China, where the recent spate of monetary tightening measures introduced by Beijing to stem the Chinese property bubble could eventually strangle the region's economic recovery, affecting our forecasts for the pharmaceutical sector. Despite having revised our 2010 Malaysian growth forecast to 6.4% in 2010 (from 4.9% previously), we believe regional weakness led by China will force Malaysia's real GDP growth to slow substantially to 3.4% in 2011, which will weigh on government finances and healthcare expenditure as a whole.
"

目录

"Executive Summary ........................................................ 7
SWOT Analysis ................................................................ 8
Malaysia Pharmaceuticals And Healthcare Industry SWOT ................................................................ 8
Malaysia Political SWOT ..................................................................................... 9
Malaysia Economic SWOT ................................................................................. 10
Malaysia Business Environment SWOT .............................................................................. 11
Pharmaceutical Business Environment Ratings ........................................ 12
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211 ................................................... 12
Rewards .............................................................................................. 13
Risks ................................................................................................... 14
Malaysia – Market Summary ......................................................... 15
Regulatory Regime ........................................................ 16
Bioequivalence .................................................................................... 17
Pharmaceutical And Medical Advertising........................................................................... 18
Labelling Requirements ...................................................................................... 18
Recent Regulatory Developments ....................................................................... 19
Intellectual Property Regime .............................................................................. 20
Counterfeit Pharmaceuticals .............................................................................. 22
Compulsory Licensing ........................................................................................ 23
Free Trade Agreements....................................................................................... 23
Pricing And Reimbursement ............................................................................... 25
Industry Trends And Developments ............................................ 26
Epidemiology ...................................................................................... 26
Table: 10 Leading Causes Of Death In Ministry of Health Hospitals, 2005 ........................................................ 27
Non-Communicable Disease ............................................................................... 28
Communicable Disease ....................................................................................... 29
Healthcare Sector ............................................................................... 31
Healthcare Sector Funding ................................................................................. 32
Medical Tourism ................................................................................. 33
Biotechnology And Research .............................................................................. 34
Table: Key Points Of The Malaysian National Biotechnology Policy .................................................. 35
Table: The Benefits Of Conducting Biotechnology Research In Malaysia ........................................................... 37
Recent Biotechnology Developments .................................................................. 39
Clinical Trials ..................................................................................... 40
Recent Developments in the Clinical Trials Industry .......................................................... 42
Medical Devices.................................................................................. 43
Leading Medical Device Players ........................................................................ 44
Recent Developments In The Medical Devices Industry...................................................................... 46
Industry Forecast Scenario ........................................................... 48
Overall Market Forecast..................................................................................... 48
Table: Pharmaceutical Sales Indicators 2007-2015 ........................................................... 49
Key Growth Factors – Industry........................................................................... 50
Table: Healthcare Expenditure Indicators 2007-2015 ....................................................... 51
Table: Government Healthcare Expenditure Indicators 2007-2015 ................................................... 52
Table: Private Healthcare Expenditure Indicators 2007-2015 ........................................................... 52
Key Growth Factors – Macroeconomic .............................................................................. 53
Table: Malaysia – Economic Activity, 2006-2015 .............................................................. 56
Prescription Drug Market Forecast .................................................................... 57
Table: Prescription Drug Sales Indicators 2007-2015 ....................................................... 58
Patented Drug Market Forecast ......................................................................... 59
Table: Patented Drug Market Indicators 2007-2015 ......................................................... 60
Generic Drug Market Forecast ........................................................................... 61
Table: Generic Drug Sales Indicators 2007-2015 .............................................................. 62
OTC Medicine Market Forecast ......................................................................... 63
Table: OTC Medicine Sales Indicators 2007-2015 ............................................................. 64
Medical Device Market Forecast ........................................................................ 65
Table: Medical Devices Sales Indicators 2007-2015 .......................................................... 66
Pharmaceutical Trade Forecast ......................................................................... 67
Table: Exports and Imports Indicators 2007-2015 ............................................................. 69
Other Healthcare Data Forecasts ....................................................................... 70
Key Risks To BMI’s Forecast Scenario ............................................................................... 71
Competitive Landscape Analysis ................................................. 72
Domestic Pharmaceutical Industry ..................................................................... 72
Foreign Pharmaceutical Industry ............................................................................ 73
Pharmaceutical Demand .................................................................................... 74
Recent Company Activities.................................................................................. 74
Table: Leading Malaysian Pharmaceutical And Healthcare Companies ............................................. 76
Halal Medicine ................................................................................... 76
Traditional Medicine .......................................................................................... 77
Pharmaceutical Distribution............................................................................... 78
Company Profiles .......................................................... 79
Leading Domestic Manufacturers ............................................................................ 79
Pharmaniaga ...................................................................................... 79
Prime Pharmaceutical ........................................................................................ 83
Bumimedic Sdn. Bhd. .......................................................................................... 84
Hovid .................................................................................................. 85
Chemical Company of Malaysia (CCM) ............................................................................. 88
Kotra Pharma ..................................................................................... 91
Multinational Companies ......................................................................................... 94
GlaxoSmithKline (GSK) ...................................................................................... 94
Pfizer .................................................................................................. 97
Novartis .............................................................................................. 99
Merck & Co .......................................................................................101
Sanofi-Aventis ....................................................................................103
Ranbaxy Malaysia .............................................................................105
Country Snapshot: Malaysia Demographic Data ...................................... 107
Section 1: Population .........................................................................................107
Table: Demographic Indicators, 2005-2030 ......................................................................107
Table: Rural/Urban Breakdown, 2005-2030 .....................................................................108
Section 2: Education And Healthcare ................................................................................108
Table: Education, 2000-2003 ............................................................................108
Table: Vital Statistics, 2005-2030 ......................................................................108
BMI Methodology ........................................................ 109
How We Generate Our Pharmaceutical Industry Forecasts ...............................................................109
Pharmaceuticals Business Environment Ratings ...............................................................110
Risk/Reward Ratings Methodology ....................................................................110
Ratings Overview ...............................................................................110
Table: Pharmaceutical Business Environment Indicators .................................................................111
Weighting ...........................................................................................112
Table: Weighting Of Components ......................................................................112
Sources ..............................................................................................112"

定购方法
① 注册订购:
点击在线订购进行报告订购
我们的服务人员将在24小时内与您联系。

② 电话订购:
拔打电话
北京:400 0090050   010-82863481
24小时:13436696826
传真:010-82601570

上海:021-64871266
021-64872612
24小时:13524982235
传真:021-64872324

签订协议
可从网上下载报告订购表或由我们传真报告订购表或订购协议。
传真:010-82601570

付款方式
① 通过银行转帐的形式支付报告购买款项
② 我们收到款项后,24小时内快递报告或者发送报告邮件

③ 款项到帐后快递发票

银行电汇:
北京:
开户行:
上海浦东发展银行北京知春路支行
帐号:91170154740001300
户名:北京佐思信息咨询有限责任公司
外币汇款账户信息:
BENEFICIARY’S BANK (受益人银行名称):
SHANGHAI PUDONG DEVELOPMENT BANK, H.O. SHANGHAI, CHINA
SWIFT:
SPDBCNSH390
BENEFICIARY’S A/C NO. (受益人帐号):
911 701 547 4000 1300
BENEFICIARY’S NAME(受益人名称):
OKOKOK(ZUOSI) Information Consulting CO.,LTD
COMPANY ADDRESS:
Room 1008, Tower A2, Longrange World Office Building, No.18 Suzhou Street, Haidian District, Beijing China
REMARKS(附言):
SHANGHAI PUDONG DEVELOPMENT BANK, BEIJING BR.***SUB-BR
在线客服系统